NICE has recommended pembrolizumab for the treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).
List view / Grid view
UK National Institute for Health and Care Excellence (NICE)
Filter the results
NICE has launched a public consultation for suggestions on updating how it selects the topics to develop guidance on, to improve medicine evaluations.
Tinostamustine has been granted Orphan Drug Designation by the European Commission to the treatment of T-cell prolymphocytic leukaemia (T-PLL).
NICE has said commonly used treatments for chronic primary pain such as paracetamol have little or no evidence that they work and should not be prescribed for the condition.
Bavencio (avelumab) and Inlyta (axitinib) are recommended by NICE for the treatment of advanced renal cell carcinoma, available on the Cancer Drugs Fund.
The recommendation of Adcetris (brentuximab vedotin) represents the first new frontline therapy for systemic anaplastic large cell lymphoma (sALCL) in several decades.
This article delves into four health technology assessment agencies, analysing the opportunities and challenges for orphan drugs in France, Germany, England and Scotland.
NICE has decided to not recommend Mayzent (siponimod) for use on the NHS as a secondary progressive multiple sclerosis treatment because its clinical trial did not directly compare it to interferon beta-1b.
The NHS is offering two contracts to pay pharma companies at the start of their research into antibiotics, to promote the development of new antimicrobials.
After three clinical trials showing its efficacy, NICE has recommended Rozlytrek (entrectinib) as treatment for non-small cell lung cancer (NSCLC).
NICE in the UK has announced it will partner with international collaborations to share its work on COVID-19 and develop guidelines for healthcare professionals.
Larotrectinib has been given a positive opinion by NICE, following the submission of a revised price after it was previously rejected.
Professor Gillian Leng has been appointed as the new Chief Executive of NICE and will take over from Sir Andrew Dillon in early April.
The UK NICE has not found pembrolizumab cost-effective for use on the NHS, after a review of evidence collected while the drug was available via the Cancer Drugs Fund.
NICE has given its positive opinion to lenalidomide in combination with rituximab as a 'chemotherapy-free' treatment for lymphoma.